These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 18331076

  • 1. Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.
    Bandello F, Augustin A, Sahel JA, Benhaddi H, Negrini C, Hieke K, Berdeaux GH, MICMAC (MICro-economics of MACular degeneration) Study Group.
    Drugs Aging; 2008; 25(3):255-68. PubMed ID: 18331076
    [Abstract] [Full Text] [Related]

  • 2. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
    Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.
    Pharmacoeconomics; 2008; 26(1):57-73. PubMed ID: 18088159
    [Abstract] [Full Text] [Related]

  • 3. Anxiety and depression prevalence rates in age-related macular degeneration.
    Augustin A, Sahel JA, Bandello F, Dardennes R, Maurel F, Negrini C, Hieke K, Berdeaux G.
    Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1498-503. PubMed ID: 17389477
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.
    Lafuma A, Brézin A, Lopatriello S, Hieke K, Hutchinson J, Mimaud V, Berdeaux G.
    Pharmacoeconomics; 2006 Apr; 24(2):193-205. PubMed ID: 16460138
    [Abstract] [Full Text] [Related]

  • 5. Treating retinal vein occlusions in France, Germany, and Italy: an analysis of treatment patterns, resource consumption, and costs.
    Augustin AJ, Sahel JA, Cerulli L, Texier-Richard B, Buchholz PM, Kobelt G.
    Eur J Ophthalmol; 2012 Apr; 22(5):776-84. PubMed ID: 22729442
    [Abstract] [Full Text] [Related]

  • 6. The burden of age-related macular degeneration: results of a cohort study in two French referral centres.
    Bonastre J, Le Pen C, Soubrane G, Quentel G.
    Pharmacoeconomics; 2003 Apr; 21(3):181-90. PubMed ID: 12558468
    [Abstract] [Full Text] [Related]

  • 7. Age-related macular degeneration: the costs to society and the patient.
    Gupta OP, Brown GC, Brown MM.
    Curr Opin Ophthalmol; 2007 May; 18(3):201-5. PubMed ID: 17435426
    [Abstract] [Full Text] [Related]

  • 8. The burden of age-related macular degeneration: a value-based medicine analysis.
    Brown GC, Brown MM, Sharma S, Stein JD, Roth Z, Campanella J, Beauchamp GR.
    Trans Am Ophthalmol Soc; 2005 May; 103():173-84; discussion 184-6. PubMed ID: 17057801
    [Abstract] [Full Text] [Related]

  • 9. [Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications].
    Pauleikhoff D, Scheider A, Wiedmann P, Gelisken F, Scholl HP, Roider I, Mohr A, Zlateva G, Xu X.
    Ophthalmologe; 2009 Mar; 106(3):242-51. PubMed ID: 18709375
    [Abstract] [Full Text] [Related]

  • 10. Cost-of-illness of psoriasis - results of a German cross-sectional study.
    Jungen D, Augustin M, Langenbruch A, Zander N, Reich K, Strömer K, Thaci D, Purwins S, Radtke M, Gutknecht M.
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):174-180. PubMed ID: 28857297
    [Abstract] [Full Text] [Related]

  • 11. Annual direct medical cost of active systemic lupus erythematosus in five European countries.
    Doria A, Amoura Z, Cervera R, Khamastha MA, Schneider M, Richter J, Guillemin F, Kobelt G, Maurel F, Garofano A, Perna A, Murray M, Schmitt C, Boucot I.
    Ann Rheum Dis; 2014 Jan; 73(1):154-60. PubMed ID: 23264339
    [Abstract] [Full Text] [Related]

  • 12. Costs and quality of life of multiple sclerosis in Germany.
    Kobelt G, Berg J, Lindgren P, Elias WG, Flachenecker P, Freidel M, König N, Limmroth V, Straube E.
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
    [Abstract] [Full Text] [Related]

  • 13. [Cost-effectiveness of photodynamic therapy in age-related macular degeneration].
    Muslera E, Natal C.
    Arch Soc Esp Oftalmol; 2006 Apr; 81(4):199-204. PubMed ID: 16688643
    [Abstract] [Full Text] [Related]

  • 14. Costs and quality of life of multiple sclerosis in Italy.
    Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A.
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
    [Abstract] [Full Text] [Related]

  • 15. Economic burden of blindness and visual impairment in Germany from a societal perspective: a cost-of-illness study.
    Chuvarayan Y, Finger RP, Köberlein-Neu J.
    Eur J Health Econ; 2020 Feb; 21(1):115-127. PubMed ID: 31493181
    [Abstract] [Full Text] [Related]

  • 16. Age-related macular degeneration: cost-of-illness issues.
    Oneill C, Jamison J, McCulloch D, Smith D.
    Drugs Aging; 2001 Feb; 18(4):233-41. PubMed ID: 11341471
    [Abstract] [Full Text] [Related]

  • 17. Health-related quality of life and utility in patients with age-related macular degeneration.
    Sahel JA, Bandello F, Augustin A, Maurel F, Negrini C, Berdeaux GH, MICMAC Study Group.
    Arch Ophthalmol; 2007 Jul; 125(7):945-51. PubMed ID: 17620576
    [Abstract] [Full Text] [Related]

  • 18. Direct medical costs of age-related macular degeneration in Italian hospital ophthalmology departments. A multicenter, prospective 1-year study.
    Garattini L, Castelnuovo E, Lanzetta P, Viscarra C, Ricci E, Parazzini F, CARMA Study Group.
    Eur J Health Econ; 2004 Feb; 5(1):22-7. PubMed ID: 15452761
    [Abstract] [Full Text] [Related]

  • 19. The impact of age-related macular degeneration on health status utility values.
    Espallargues M, Czoski-Murray CJ, Bansback NJ, Carlton J, Lewis GM, Hughes LA, Brand CS, Brazier JE.
    Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4016-23. PubMed ID: 16249475
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.